Nya Zeeland - engelska - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - loperamide hydrochloride 2mg;  ;   - orodispersible tablet - 2 mg - active: loperamide hydrochloride 2mg     excipient: aspartame gelatin mannitol mint flavour 051296 tp0551 purified water sodium bicarbonate

Irland - engelska - HPRA (Health Products Regulatory Authority)

johnson & johnson (ireland) limited - loperamide hydrochloride; simeticone - tablet - 2 mg/125 milligram(s) - antipropulsives; loperamide, combinations

Irland - engelska - HPRA (Health Products Regulatory Authority)

jntl consumer health i (ireland) limited - loperamide hydrochloride; simeticone - tablet - antipropulsives; loperamide, combinations

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 1004.43 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 148.91 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - augmentin duo forte is indicated for the short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology) *urinary tract infections (uncomplicated and complicated); *lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; *upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; *skin and skin structure infection appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin duo forte. however when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the product information, therapy may be instituted prior to obtaining the results of bacteriological and susceptibility studies. once the results are known, therapy should be adjusted should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo forte should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo forte.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - amoxicillin trihydrate, quantity: 1004.43 mg (equivalent: amoxicillin, qty 875 mg); potassium clavulanate, quantity: 151.92 mg (equivalent: clavulanic acid, qty 125 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; titanium dioxide; hypromellose; propylene glycol; purified talc; ethylcellulose - augmentin duo forte is indicated for the short term treatment of bacterial infections at the following sites when caused by sensitive organisms (refer to microbiology) *urinary tract infections (uncomplicated and complicated); *lower respiratory tract infections, including community acquired pneumonia and acute exacerbations of chronic bronchitis; *upper respiratory tract infections, such as sinusitis, otitis media and recurrent tonsillitis; *skin and skin structure infection appropriate culture and susceptibility studies should be performed to identify the causative organism(s) and determine its (their) susceptibility to augmentin duo forte. however when there is reason to believe an infection may involve any of the beta-lactamase producing organisms listed in the product information, therapy may be instituted prior to obtaining the results of bacteriological and susceptibility studies. once the results are known, therapy should be adjusted should be adjusted if appropriate. the treatment of mixed infections caused by amoxycillin susceptible organisms and beta-lactamase producing organisms susceptible to augmentin duo forte should not require the addition of another antibiotic due to the amoxycillin content of augmentin duo forte.

Kanada - engelska - Health Canada

mcneil consumer healthcare division of johnson & johnson inc - loperamide hydrochloride; simethicone - tablet - 2mg; 125mg - loperamide hydrochloride 2mg; simethicone 125mg - antidiarrhea agents

Malaysia - engelska - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn bhd - loperamide hydrochloride -

Belgien - engelska - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

johnson & johnson consumer sa-nv - loperamide hydrochloride 2 mg - orodispersible tablet - 2 mg - loperamide hydrochloride 2 mg - loperamide

USA - engelska - NLM (National Library of Medicine)

mcneil consumer healthcare - loperamide hydrochloride (unii: 77ti35393c) (loperamide - unii:6x9oc3h4ii) - capsule - 2 mg - imodium® (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. imodium® is also indicated for reducing the volume of discharge from ileostomies. imodium is contraindicated in patients with a known hypersensitivity to loperamide hydrochloride or to any of the excipients. imodium is contraindicated in patients with abdominal pain in the absence of diarrhea. imodium is not recommended in infants below 24 months of age. imodium should not be used as the primary therapy: a specific clinical study designed to assess the abuse potential of loperamide at high doses resulted in a finding of extremely low abuse potential. studies in morphine-dependent monkeys demonstrated that loperamide hydrochloride at doses above those recommended for humans prevented signs of morphine withdrawal. however, in humans, the naloxone challenge pupil test, which when positive indicates opiate-like effects, performed

Storbritannien - engelska - MHRA (Medicines & Healthcare Products Regulatory Agency)

mcneil products ltd - loperamide hydrochloride; simeticone - oral tablet - 2mg ; 125mg